Amgen has agreed to acquire 95.6% of the shares of the Turkish injectable generics company Mustafa Nevzat Pharmaceuticals (MN Pharmaceuticals) in a deal that values the company at approximately US$700 M. The deal will further Amgen’s broad international expansion strategy. The company established an affiliate in Turkey in 2010 and currently markets two products in the country. MN Pharmaceuticals reported revenues of approximately US$200 M in 2011 and has been growing at a double-digit rate in local currency over the past 5 years.